Drug found effective in treatment of severe aplastic anemia

A study conducted by NHLBI researchers found that the drug eltrombopag improves the response to treatment in patients with severe aplastic anemia. “Eltrombopag plus standard immunosuppressive therapy appeared to increase the overall response rate and substantially increase the frequency, speed and robustness of hematologic recovery in patients with SAA compared to historical controls,” said NHLBI researcher and the study’s lead author, Danielle Townsley, MD. The findings appear in the The New England Journal of Medicine.

Healio: Eltrombopag shows promise as first treatment for severe aplastic anemia

PharmaTimes: Data back first-line use of Novartis’ eltrombopag in SAA

Hematology Times: Combo improves response rates in treatment-naïve SAA

RareDR: Should Second-line Aplastic Anemia Drug Be a First-line Option?

GlobeNewswire: NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia